Hadassah Medical Center, a leading healing, teaching, and research hospital in Jerusalem, Israel, is the first medical center in the country to join the TriNetX global health research network to increase clinical trial activity and help pharmaceutical companies improve the protocol design and feasibility process.
Prof. Zeev Rotstein, Director General of Hadassah Medical Organization welcomed this new scientific partnership in the field of clinical trials: “The New Hadassah is at the forefront of research, both in Israel and in the international arena. Hadassah’s physicians and researchers very proudly represent the significant achievements that contribute to the advancement of medicine of the future. In this way they improve patients’ chances to benefit from good health and better quality of life. I commend this new partnership that will no doubt lead us all to impressive new achievements.”
Hadassah is a leading hospital complex in Israel with two campuses, 1,300 beds, 45 operating theaters and seven special intensive care units. Together with The Hebrew University of Jerusalem, Hadassah provides education and clinical experience through five schools of medical professions. The physicians and researchers of Hadassah have gained global recognition through ground breaking research and success in biomedical technology—including novel therapeutics, diagnostics and devices. Hadassah accounts for more than half of all hospital research conducted in Israel.
“We want to collaborate better with pharma, CROs and other research centers,” said Keren Musiya, MSc, MBA, Director, Clinical Trials Unit (CTU) at Hadassah. “Being part of TriNetX will allow us to enhance our efficiencies, provide access to advanced analytical tools for our investigators and physicians, and raise our visibility with sponsors to attract new trials.”
TriNetX’s cloud-based platform, TNX™, provides on-demand access to longitudinal clinical data and a set of highly intuitive analytics capabilities, enabling researchers to design successful protocols, improve site selection and planning, and create real-world evidence. TriNetX has partnered with leading healthcare organizations, spanning 15 countries, to create a global health research network representing over 100 million patients.
“We are excited to have Hadassah Medical Center become part of our growing international presence,” said Gadi Lachman, CEO of TriNetX. “We believe the added exposure to our pharmaceutical members will prove enormously beneficial for Hadassah.”